نتائج البحث - "Mahon, Francois-Xavier"

1

دورية أكاديمية

How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen

المؤلفون: Pfirrmann, Markus, Saussele, Susanne, Mahon, François-Xavier, Richter, Johan

المصدر: Leukemia ; volume 38, issue 2, page 460-462 ; ISSN 0887-6924 1476-5551

مصطلحات موضوعية: Oncology, Cancer Research, Hematology

الإتاحة: https://doi.org/10.1038/s41375-023-02124-3Test
https://www.nature.com/articles/s41375-023-02124-3.pdfTest
https://www.nature.com/articles/s41375-023-02124-3Test

View record in BASE

2

مؤتمر

المصدر: Efficace , F , Francois-Xavier Mahon , F-X , Richter , J , Piciocchi , A , Cipriani , M , Nicolini , F E , Hjorth-Hansen , H , Almeida , A , Janssen , J J W M , Mayer , J , Koskenvesa , P , Panayiotidis , P , Olsson-Strömberg , U , Martínez-López , J , Rousselot , P , Vestergaard , H , Ehrencrona , H , Kairisto , V , Poláková , K M , Mustjoki , S , Berger , M G , Hochhaus , A , Pfirrmann , M & ....

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/41c732fe-281b-4bf7-bbce-f402c574f974Test

الإتاحة: https://doi.org/10.1097/01.HS9.0000967548.09724.54Test
https://portal.findresearcher.sdu.dk/da/publications/41c732fe-281b-4bf7-bbce-f402c574f974Test

View record in BASE

3

دورية أكاديمية

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

المصدر: Mauro , M J , Hughes , T P , Kim , D-W , Rea , D , Cortes , J E , Hochhaus , A , Sasaki , K , Breccia , M , Talpaz , M , Ottmann , O , Minami , H , Goh , Y T , DeAngelo , D J , Heinrich , M C , Gómez-García de Soria , V , le Coutre , P , Mahon , F-X , Janssen , J J W M , Deininger , M , Shanmuganathan , N , Geyer , M B , Cacciatore , ....

العلاقة: https://research.vumc.nl/en/publications/6d526334-4128-4e79-a87b-30d3fb304c73Test

الإتاحة: https://doi.org/10.1038/s41375-023-01860-wTest
https://research.vumc.nl/en/publications/6d526334-4128-4e79-a87b-30d3fb304c73Test
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150733462&origin=inwardTest
https://www.ncbi.nlm.nih.gov/pubmed/36949155Test

View record in BASE

4

دورية أكاديمية

المصدر: HemaSphere ; volume 7, issue S3, page e0972454 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000967548.09724.54Test

View record in BASE

5

دورية أكاديمية

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE

المؤلفون: Hochhaus, Andreas, Saussele, Susanne, Mahon, Francois-Xavier, Pilipovic, Virginia, Zhang, Yifan, Schuld, Peter, Brümmendorf, Tim H

المصدر: HemaSphere ; volume 7, issue S3, page e5851092 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000974704.58510.92Test

View record in BASE

6

دورية أكاديمية

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

المؤلفون: Shah, Neil P., García‐Gutiérrez, Valentín, Jiménez‐Velasco, Antonio, Larson, Sarah M., Saussele, Susanne, Rea, Delphine, Mahon, François‐Xavier, Levy, Moshe Yair, Gómez‐Casares, María Teresa, Mauro, Michael J., Sy, Oumar, Martin‐Regueira, Patricia, Lipton, Jeffrey H.

المصدر: British Journal of Haematology ; volume 202, issue 5, page 942-952 ; ISSN 0007-1048 1365-2141

الإتاحة: https://doi.org/10.1111/bjh.18883Test

View record in BASE

7

دورية أكاديمية

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐ STIM study

المؤلفون: Dulucq, Stéphanie, Rigal‐Huguet, Françoise, Nicolini, Franck E., Cony‐Makhoul, Pascale, Escoffre‐Barbe, Martine, Gardembas, Martine, Legros, Laurence, Rousselot, Philippe, Liu, Jixing, Rea, Delphine, De Mas, Véronique, Hayette, Sandrine, Raynaud, Sophie, Lacoste‐Roussillon, Caroline, Robbesyn, Fanny, Klein, Emilie, Morisset, Stéphane, Mahon, François‐Xavier, Etienne, Gabriel

المساهمون: Novartis Pharma

المصدر: British Journal of Haematology ; volume 201, issue 6, page 1116-1124 ; ISSN 0007-1048 1365-2141

الإتاحة: https://doi.org/10.1111/bjh.18796Test

View record in BASE

8

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

المؤلفون: Richter, Johan, Lübking, Anna, Söderlund, Stina, Lotfi, Kourosh, Markevärn, Berit, Själander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, 1974, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Žáčková, Daniela, Mayer, Jiří, Olsson-Strömberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, Koskenvesa, Perttu

المصدر: Leukemia. 35(8):2416-2418

وصف الملف: print

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-89665Test
https://doi.org/10.1038/s41375-021-01173-wTest

View record in SwePub

9

دورية أكاديمية

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.

المصدر: Journal of Clinical Oncology; 2024 Supplement 16, Vol. 42, p1875-1880, 11p

10

كتاب

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

المؤلفون: Richter, Johan, Lubking, Anna, Soderlund, Stina, Lotfi, Kourosh, Markevarn, Berit, Sjalander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Zackova, Daniela, Mayer, Jiri, Olsson-Stromberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, Koskenvesa, Perttu

المساهمون: HUS Comprehensive Cancer Center, Department of Medicine, Hematologian yksikkö, Department of Oncology

مصطلحات موضوعية: 3122 Cancers

وصف الملف: application/pdf

العلاقة: We thank all hematologists, study coordinators, and study nurses who have reported patients to AFTER-SKI. Funding for this project was provided from Lund University and Skane University Hospital to JR.; Richter , J , Lubking , A , Soderlund , S , Lotfi , K , Markevarn , B , Sjalander , A , Stenke , L , Deneberg , S , Ahlstrand , E , Myhr-Eriksson , K , Panayiotidis , P , Gedde-Dahl , T , Zackova , D , Mayer , J , Olsson-Stromberg , U , Mahon , F-X , Saussele , S , Hjorth-Hansen , H & Koskenvesa , P 2021 , ' Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI ' , Leukemia , vol. 35 , no. 8 , pp. 2416-2418 . https://doi.org/10.1038/s41375-021-01173-wTest; 2d297d5e-bf89-4dbf-b9e9-a5bf99588f5a; http://hdl.handle.net/10138/340176Test; 000618175800004

الإتاحة: http://hdl.handle.net/10138/340176Test

View record in BASE

تنقيح النتائج